China approves Bio-Thera Solutions' biosimilar to Actemra 17-Jan-2023 By Rachel Arthur The China National Medical Products Administration (NMPA) has approved BAT1806, a biosimilar of Actemra (tocilizumab), in China.
Roche’s treatment for coronavirus enters Phase III 19-Mar-2020 By Ben Hargreaves Roche looks to repurpose its arthritis medicine for use against the coronavirus, after China previously endorsed its use.
China’s Bio-Thera begins trials to develop biosimilar to Actemra 01-Aug-2018 By Maggie Lynch A Phase I clinical trial to examine the safety and pharmacokinetics of BAT1806, an Actemra biosimilar, is to be conducted by Chinese pharmaceutical company Bio-Thera.